P
Ping Chen
Publications - 5
Citations - 285
Ping Chen is an academic researcher. The author has contributed to research in topics: Diabetes mellitus & IDH1. The author has an hindex of 3, co-authored 5 publications receiving 195 citations.
Papers
More filters
Journal ArticleDOI
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller,Lemieux Rene M,Erin Artin,Jeffrey O. Saunders,Francesco G. Salituro,Jeremy Travins,Giovanni Cianchetta,Zhenwei Cai,Ding Zhou,Cui Dawei,Ping Chen,Kimberly Straley,Erica Tobin,Fang Wang,Muriel D. David,Virginie Penard-Lacronique,Cyril Quivoron,Véronique Saada,Stéphane de Botton,Stefan Gross,Lenny Dang,Hua Yang,Luke Utley,Yue Chen,Hyeryun Kim,Shengfang Jin,Zhiwei Gu,Gui Yao,Zhiyong Luo,Xiaobing Lv,Cheng Fang,Liping Yan,Andrew J. Olaharski,Lee Silverman,Scott A. Biller,Shinsan M. Su,Katharine E. Yen +36 more
TL;DR: AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo is reported.
Patent
Novel antiviral compounds
TL;DR: In this article, the present invention relates to a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection such as HIV using the same.
Patent
Alkyne-bridged hetero-aromatics and uses thereof
TL;DR: In this paper, a novel alkyne-bridged hetero-aromatics as described in the specification which are PDE10A inhibitors are used for the treatment of neurological, psychiatric disorder, metabolic disorders, such as Schizophrenia, Parkinson's disease, Huntington's disease and Alzheimer's disease.
Patent
Novel antivirus compound
TL;DR: In this article, a compound of which the structure is shown as a general formula I, or an enantiomer, a diastereomer, or a dynamic isomer or a pharmaceutically acceptable salt or solvate thereof is described.
Patent
Mixed aromatic compound of alkynyl bridging and application thereof
TL;DR: In this article, a mixed aromatic compound of alkynyl bridging is used for treating nerve and psychical diseases and diseases like metabolic disturbance, which is shown in general formula I or a general formula II.